Horizon Pharma plc, a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the presentation of data from a Phase 2 clinical study of ACTIMMUNE® (interferon gamma-1b) treatment in children with Friedreich’s ataxia (FA). Read more.
October 9, 2014 |   Press Release
Horizon Pharma plc Announces Presentation of ACTIMMUNE(R) Phase 2 Data in Friedreich’s Ataxia
October 7, 2014 |   In the News
Smart-Bug Maker Synlogic Nabs $5M From Gates Foundation
Synlogic, one of the newer biotech startups to come out of Cambridge, MA, already strung together nearly $30 million when it announced its launch in July. Now it’s topping off that round with some financial support from the Bill & Melinda Gates Foundation to help tackle some of the world’s bigger health problems. Read more.
October 6, 2014 |   From the Trenches
Should I Stay Or Should I Go? Big Pharma Execs Taking The Biotech Plunge
That’s the dilemma facing drug hunters as leadership roles in biotech become more and more attractive. You may have noticed that more and more seasoned pharma executives are making the move from big pharma or big biotech to lead small biotech companies. Read more.
October 2, 2014 |   In the News
Atlas to split life sciences, tech businesses
Cambridge-based venture capital firm Atlas Venture will split, with its life sciences and technology franchises becoming separate companies. Read more.
October 1, 2014 |   Press Release
Zafgen Announces Initiation of Phase 3 trial of Beloranib in Prader-Willi Syndrome
Zafgen today announced that it has initiated the first Phase 3 clinical trial, in the United States, with its lead product candidate, beloranib, in the treatment of Prader-Willi syndrome (PWS). PWS is a rare disease and the most common known genetic cause of life-threatening obesity. Read more.